Ignite Creation Date:
2025-12-24 @ 6:40 PM
Ignite Modification Date:
2026-01-01 @ 12:40 PM
Study NCT ID:
NCT05263557
Status:
UNKNOWN
Last Update Posted:
2023-07-25
First Post:
2021-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011085', 'term': 'Polycystic Ovary Syndrome'}, {'id': 'D007333', 'term': 'Insulin Resistance'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}], 'ancestors': [{'id': 'D010048', 'term': 'Ovarian Cysts'}, {'id': 'D003560', 'term': 'Cysts'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D006946', 'term': 'Hyperinsulinism'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003687', 'term': 'Dehydroepiandrosterone'}, {'id': 'C011657', 'term': 'adrenosterone'}], 'ancestors': [{'id': 'D000737', 'term': 'Androstenols'}, {'id': 'D000736', 'term': 'Androstenes'}, {'id': 'D000731', 'term': 'Androstanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D015068', 'term': '17-Ketosteroids'}, {'id': 'D007664', 'term': 'Ketosteroids'}, {'id': 'D000305', 'term': 'Adrenal Cortex Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D045165', 'term': 'Testosterone Congeners'}, {'id': 'D012739', 'term': 'Gonadal Steroid Hormones'}, {'id': 'D042341', 'term': 'Gonadal Hormones'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Interventional'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 20}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2022-08-19', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-06', 'completionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-07-24', 'studyFirstSubmitDate': '2021-10-20', 'studyFirstSubmitQcDate': '2022-02-21', 'lastUpdatePostDateStruct': {'date': '2023-07-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-03-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Relative change in glucose disposal from baseline with 11KA4 administration compared to that seen with DHEA', 'timeFrame': '7 Days', 'description': 'Utilizing hyperglycaemic-euglycaemic clamp (μmol/min/kg)'}], 'secondaryOutcomes': [{'measure': 'Relative change in glucose oxidation from baseline with 11KA4 administration compared to that seen with DHEA', 'timeFrame': '7 Days', 'description': 'Measured by 13C-breath testing (mg/kg/min)'}, {'measure': 'Relative change in endogenous glucose production from baseline with 11KA4 administration compared to that seen with DHEA (μmol/min/kg)', 'timeFrame': '7 Days', 'description': 'Utilizing hyperglycaemic-euglycaemic clamp (μmol/min/kg)'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['PCOS'], 'conditions': ['Polycystic Ovary Syndrome', 'Insulin Resistance', 'Androgen; Hypersecretion', 'Endocrine System Diseases']}, 'descriptionModule': {'briefSummary': 'Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS). Serum testosterone correlates with insulin resistance in PCOS, however, there is an urgent need to improve our understanding of the association between androgens and the risk of type 2 diabetes.\n\n11-oxygenated steroids are the predominant androgens in PCOS and correlate closely with markers of insulin resistance. The bioactive 11-oxygenated androgen 11-ketotestosterone (11KT) binds and activates the androgen receptor with equal affinity to testosterone, yet nothing is known about its impact on metabolism or glucose homeostasis\n\nCrucially, there are no data linking androgen excess with muscle glucose metabolism and the differential contribution of 11-oxygenated androgens to diabetes risk through these processes remains unknown.\n\nThe investigators hypothesise the following:\n\n1. Oral androgen exposure in women with PCOS results in distinct changes in tissue-specific insulin sensitivity and muscle energy biogenesis\n2. 11-oxygenated androgen exposure exerts differential changes on the above parameters in comparison to classic androgen exposure\n\nThe study has the following aims:\n\n1. To examine the impact of oral androgen exposure on skeletal muscle insulin sensitivity and glucose disposal in women with PCOS.\n2. To delineate the impact of androgen exposure on muscle mitochondrial function ex vivo in women with PCOS\n3. To compare the differential impact of 11-oxygenated androgen compared to classic androgens on glucose disposal and muscle mitochondrial function\n\nThe two arms will run in parallel and all participants will undergo identical investigations before and after 7 days of either DHEA or 11KA4.\n\nInvestigations will include baseline arthrometric measurements muscle biopsy, two-step hyperinsulinaemic euglycaemic clamp, breath sampling.\n\nThis interventional metabolic phenotyping study will probe the role of classic and 11-oxygenated androgens in metabolic dysfunction in PCOS using gold-standard in vivo metabolic phenotyping techniques. Delineating the distinct contribution of 11-oxygenated androgens, through effects on skeletal muscle biology, to the risk of T2DM is an important step in the process of determining risk of type 2 diabetes in this vulnerable cohort.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT'], 'maximumAge': '40 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Women with a confirmed diagnosis polycystic ovary syndrome with androgen excess on clinical or biochemical grounds\n* BMI 20.0-39.9kg/m2\n* Age range 18-40 years\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* A confirmed diagnosis of diabetes\n* Current or recent (\\<3-months) use of weight loss medications\n* Current or recent use of oral contraceptive pill or hormone replacement therapy (within 3-months)\n* Blood haemoglobin \\<12.0g/dL\n* History of alcoholism or a greater than recommended alcohol intake (recommendations \\> 21 units on average per week for men and \\> 14 units on average per week for women)\n* Haemorrhagic disorders or Treatment with anticoagulant agents\n* Any medical condition in the opinion of the investigator that might impact upon safety or validity of the results\n* Pregnancy or breastfeeding at the time of planned recruitment\n* A diagnosis of PCOS according to Rotterdam criteria where the patient does not have clinical or biochemical evidence of androgen excess\n* History of significant renal (eGFR\\<30) or hepatic impairment (AST or ALT \\>two-fold above ULN; pre-existing bilirubinaemia \\>1.2 ULN)\n* Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.\n* Current intake of drugs known to impact upon steroid or metabolic function or intake of such drugs during the six months preceding the planned recruitment"}, 'identificationModule': {'nctId': 'NCT05263557', 'acronym': 'DIMOXIS', 'briefTitle': 'Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)', 'organization': {'class': 'OTHER', 'fullName': 'Royal College of Surgeons, Ireland'}, 'officialTitle': 'Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS)', 'orgStudyIdInfo': {'id': 'DIMOXIS'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'DHEA', 'description': 'Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.', 'interventionNames': ['Dietary Supplement: Dehydroepiandrosterone (DHEA)']}, {'type': 'EXPERIMENTAL', 'label': '11KA4', 'description': 'Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.', 'interventionNames': ['Dietary Supplement: 11-ketoandrostenedione (11KA4)']}], 'interventions': [{'name': 'Dehydroepiandrosterone (DHEA)', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.', 'armGroupLabels': ['DHEA']}, {'name': '11-ketoandrostenedione (11KA4)', 'type': 'DIETARY_SUPPLEMENT', 'description': '11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.', 'armGroupLabels': ['11KA4']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Dublin', 'status': 'RECRUITING', 'country': 'Ireland', 'contacts': [{'name': "Michael O'Reilly", 'role': 'CONTACT', 'email': 'michaelworeilly@rcsi.ie', 'phone': '018093894'}], 'facility': 'Beaumont Hospital', 'geoPoint': {'lat': 53.33306, 'lon': -6.24889}}], 'centralContacts': [{'name': "Michael W O'Reilly", 'role': 'CONTACT', 'email': 'michaelworeilly@rcsi.ie', 'phone': '018093894'}], 'overallOfficials': [{'name': 'Michael W Michael', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'RCSI Education & Research Centre, Beaumont Hospital, Beaumont Dublin 9 Ireland Ireland'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Royal College of Surgeons, Ireland', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Oxford', 'class': 'OTHER'}, {'name': 'University of Birmingham', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}